NCT00130156View on ClinicalTrials.gov

Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in the Treatment of Patients With Mild to Moderate Essential Hypertension

PHASE4CompletedINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

September 30, 2008

Study Completion Date

March 31, 2009

Conditions
High Blood Pressure
Interventions
DRUG

Bunazosin

Patients will be randomized to the add-on treatment with Bunazosin (Detantol-R) 3 mg once-daily after breakfast for a total of eight weeks.

DRUG

Doxazosin

Patients will be randomized to the add-on treatment with Doxazosin (Doxaben XL) 4 mg once-daily after breakfast for a total of eight weeks.

DRUG

Valsartin

After wash-out period, the eligible subjects will be treated with Valsartin (Diovan) 80 mg as the mono therapy for 5 weeks. If the blood pressures are inadequately responded, then the patients will be randomized to either Bunazosin (Detantol-R) or Doxazosin (Doxaben XL) along with Valsartin as the add-on treatment for 8 weeks.

Trial Locations (1)

Unknown

National Taiwan University Hospital., Taipei

All Listed Sponsors
collaborator

Eisai Co., Ltd.

INDUSTRY

lead

Eisai Inc.

INDUSTRY

NCT00130156 - Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in the Treatment of Patients With Mild to Moderate Essential Hypertension | Biotech Hunter | Biotech Hunter